Novel combination of efti with KEYTRUDA® and chemotherapy generates strong response rates across all PD-L1 expression levels in first line ...

October 2025 Tezspire approved in the US for chronic rhinosinusitis with nasal polyps Approval broadens indication for Tezspire to a second disease characterised by epithelial-driven inflammationAstra ...

In a case that was billed as profits versus patients, India’s Supreme Court dismissed a petition in which Roche sought to ...

The parents of two boys born with a rare genetic disorder have demanded the rollout of a life-changing heel prick test – ...

The Supreme Court has given the go-ahead to Natco Pharma for launching its generic version of Risdiplam in India, dismissing the appeal filed by Swiss drugmaker F. Hoffmann-La Roche ...

In a huge setback for Swiss pharma major Roche, the Supreme Court on Friday dismissed its petition challenging a Delhi High ...

Nearly all children with spinal muscular atrophy who started on Evrysdi before symptom onset are walking after three years, ...

The Supreme Court upheld Delhi HC's interim order allowing Natco Pharma to manufacture and sell a generic version of Roche's ...

Imagine a child born in a family with a rare disease, whose treatment would cost more than 17 crore for a single dose. The ...

In a major escalation of the patent battle over a life-saving rare disease drug, Swiss pharmaceutical giant F. Hoffmann-La ...

Gene therapy is linked to better nonmotor outcomes in spinal muscular atrophy type 1 compared to first-line nusinersen, new ...